Napo Pharmaceuticals Announces The Successful Production Of Crofelemer Active Pharmaceutical Ingredient

... Napo Pharmaceuticals, Inc., (LSE: NAPL), which focuses on the development and commercialization of proprietary pharmaceuticals for the global marketplace in collaboration with local partners, announces the successful production of crofelemer Active Pharmaceutical Ingredient ("API") for use in a final pivotal phase 3 trial for chronic diarrhea in people living with HIV/AIDS. [click link for full article] ...